Starling Oncology, Inc. (STLN) Net margin 2020–2025
Starling Oncology, Inc. (STLN) net profit margin by fiscal year — reported net income divided by reported revenue.
-12.1%FY2025 · since FY2020: -7.6% → -12.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -12.1% | +4.4 pp |
| FY2024 | -16.4% | +9.2 pp |
| FY2023 | -25.6% | -25.7 pp |
| FY2022 | 0.1% | +5.4 pp |
| FY2021 | -5.4% | +2.3 pp |
| FY2020 | -7.6% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More STLN financial trends
STLN RevenueSTLN Net incomeSTLN Gross profitSTLN Gross marginSTLN Operating incomeSTLN Operating marginSTLN Operating cash flowSTLN Free cash flowSTLN Capital expendituresSTLN Return on equitySTLN Stock buybacksSTLN Dividends paidSTLN Total assetsSTLN Total liabilitiesSTLN Shareholders’ equitySTLN overview →